Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.
about
Prevention and treatment of bone changes associated with exposure to glucocorticoidsEffect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing SpondylitisSkeletal and extraskeletal actions of denosumab.Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls.
P2860
Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Soluble receptor activator of ...... lupus erythematosus patients.
@ast
Soluble receptor activator of ...... lupus erythematosus patients.
@en
type
label
Soluble receptor activator of ...... lupus erythematosus patients.
@ast
Soluble receptor activator of ...... lupus erythematosus patients.
@en
prefLabel
Soluble receptor activator of ...... lupus erythematosus patients.
@ast
Soluble receptor activator of ...... lupus erythematosus patients.
@en
P2860
P50
P356
P1476
Soluble receptor activator of ...... lupus erythematosus patients.
@en
P2093
Helena Canhão
P2860
P2888
P356
10.1186/AR3500
P577
2011-10-25T00:00:00Z
P5875
P6179
1008875009